ProQR Therapeutics N.V.
PRQR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $2,915 | $3,817 | $4,519 | $4,307 |
| % Growth | -23.6% | -15.5% | 4.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $2,915 | $3,817 | $4,519 | $4,307 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $11,080 | $11,408 | $12,323 | $10,611 |
| G&A Expenses | $3,119 | $4,816 | $3,234 | $3,913 |
| SG&A Expenses | $3,119 | $4,816 | $3,234 | $3,913 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$158 | -$222 | -$136 |
| Operating Expenses | $14,199 | $16,066 | $15,335 | $14,388 |
| Operating Income | -$11,284 | -$12,249 | -$10,816 | -$10,081 |
| % Margin | -387.1% | -320.9% | -239.3% | -234.1% |
| Other Income/Exp. Net | $278 | $88 | $737 | $776 |
| Pre-Tax Income | -$11,006 | -$12,161 | -$10,079 | -$9,305 |
| Tax Expense | $0 | $18 | $0 | $0 |
| Net Income | -$11,006 | -$12,179 | -$10,079 | -$9,305 |
| % Margin | -377.6% | -319.1% | -223% | -216% |
| EPS | -0.1 | -0.12 | -0.1 | -0.11 |
| % Growth | 16.7% | -20% | 9.1% | – |
| EPS Diluted | -0.1 | -0.12 | -0.1 | -0.11 |
| Weighted Avg Shares Out | 105,346 | 105,344 | 105,297 | 81,666 |
| Weighted Avg Shares Out Dil | 110,060 | 105,344 | 105,297 | 81,666 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $192 | $455 | $704 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $671 | $675 | $678 | $671 |
| EBITDA | -$10,335 | -$11,574 | -$10,138 | -$5,821 |
| % Margin | -354.5% | -303.2% | -224.3% | -135.2% |